Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption
- 31 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 26 (4), 498-+
- https://doi.org/10.1038/s41591-020-0774-y
Abstract
We administered Ad26, modified vaccinia Ankara vectors containing mosaic HIV-1 antigens or placebo in 26 individuals who initiated antiretroviral therapy during acute human immunodeficiency virus infection as an exploratory study to determine the safety and duration of viremic control after treatment interruption. The vaccine was safe and generated robust immune responses, but delayed time to viral rebound compared to that in placebo recipients by only several days and did not lead to viremic control after treatment interruption (clinical trial NCT02919306). Test of therapeutic mosaic vaccines in HIV-infected individuals shows no control of virus after treatment interruption.Funding Information
- Henry M. Jackson Foundation (W81XWH-07-2-0067)
- United States Department of Defense | Biometrics Identity Management Agency (W81XWH-07-2-0067)
This publication has 31 references indexed in Scilit:
- First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1PLOS ONE, 2018
- Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)The Lancet, 2018
- First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara VectorThe Journal of Infectious Diseases, 2018
- Delayed differentiation of potent effector CD8 + T cells reducing viremia and reservoir seeding in acute HIV infectionScience Translational Medicine, 2017
- Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeysNature, 2016
- Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East AfricaAIDS, 2016
- International AIDS Society global scientific strategy: towards an HIV cure 2016Nature Medicine, 2016
- Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV SerologyClinical Infectious Diseases, 2016
- Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI StudyPLoS Pathogens, 2013
- Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeysNature Medicine, 2010